Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

January 12, 2018: By Jon Swedien
Bausch + Lomb's Stellaris Elite

Bausch + Lomb’s Stellaris Elite

Bausch + Lomb has received CE marking for the Stellaris Elite dual-function cataract/vitrectomy system, which includes the Vitesse hypersonic vitrector, the company announced Jan. 8.

The Stellaris Elite offers adaptive fluidics, designed to provide precise aspiration control with predictive infusion management to create a responsive and controlled surgical environment for efficient lens removal, the company said.

The Vitesse vitrector uses a novel, single-needle design and continuously open port system. Vitesse is available exclusively on the Stellaris Elite.

The Stellaris Elite platform is now available in the 28 European Union countries and Iceland, Liechtenstein, Norway, and Switzerland, according to Bausch + Lomb, a New Jersey-based subsidiary of Canada’s Valeant. The platform gained US approval in April 2017.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Optical Coherence Tomography Report: A Global Market Analysis for 2017 to 2023